ValuEngine cut shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) from a hold rating to a sell rating in a research note published on Wednesday.

A number of other analysts also recently weighed in on NTLA. Oppenheimer Holdings, Inc. started coverage on shares of Intellia Therapeutics in a report on Tuesday, July 18th. They issued a market perform rating for the company. Jefferies Group LLC reissued a buy rating and issued a $36.00 price target on shares of Intellia Therapeutics in a report on Saturday, July 22nd. Cann reissued a hold rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Chardan Capital reissued a buy rating and issued a $20.00 price target (up from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. Finally, Barclays PLC started coverage on shares of Intellia Therapeutics in a report on Wednesday, September 6th. They issued an overweight rating and a $29.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $30.17.

Intellia Therapeutics (NASDAQ:NTLA) traded up $0.17 during midday trading on Wednesday, hitting $19.72. 600,411 shares of the company traded hands, compared to its average volume of 325,717. Intellia Therapeutics has a fifty-two week low of $10.83 and a fifty-two week high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The business had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. Intellia Therapeutics’s quarterly revenue was up 49.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) EPS. analysts anticipate that Intellia Therapeutics will post -1.68 earnings per share for the current year.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/16/intellia-therapeutics-inc-ntla-downgraded-to-sell-at-valuengine.html.

Several hedge funds have recently made changes to their positions in the company. Airain ltd raised its stake in shares of Intellia Therapeutics by 3.8% in the 2nd quarter. Airain ltd now owns 28,077 shares of the company’s stock valued at $449,000 after buying an additional 1,027 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Intellia Therapeutics by 6.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 26,903 shares of the company’s stock valued at $380,000 after buying an additional 1,539 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Intellia Therapeutics by 5.6% in the 1st quarter. Bank of New York Mellon Corp now owns 31,676 shares of the company’s stock valued at $446,000 after buying an additional 1,682 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Intellia Therapeutics by 61.3% in the 3rd quarter. SG Americas Securities LLC now owns 10,169 shares of the company’s stock valued at $253,000 after buying an additional 3,863 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Intellia Therapeutics by 6.0% in the 1st quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock valued at $1,072,000 after buying an additional 4,291 shares in the last quarter. Institutional investors own 47.43% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.